Received Dec 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | Y015180 | — |
No additional AE; Patient was administered their second dose of GARDASIL 9 earlier than the recommended interval within the PI; This Spontaneous report was received from a pharmacist and referred to a patient of unknown age and gender. The patient's medical history, past medications, and concomitant medications were not reported. On 19-Nov-2025, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) suspension for injection (dose, route of administration, anatomical location, lot number and expiry date were not reported) as prophylaxis. On 17-Dec-2025, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) Suspension for injection in pre-filled syringe, 0.5 mL, total, (valid lot number: Y015180, expiration date reported and confirmed as 28-Jan-2027) as prophylaxis earlier than the recommended interval (Inappropriate schedule of product administration). No symptoms reported (no adverse event). Batch/Lot number is being requested and will be submitted if received.